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Abstract
Background: The desired (therapeutic) and undesired (side) effects of methylphenidate might have underlying
correlations. The aim of this study was to explore the strength and the possible sources of these correlations.
Methods: One hundred and fifty-seven children with ADHD (6-12 years) were administered placebo and
methylphenidate (0.5 mg/kg in a divided b.i.d. dose), each for a one-week period, in a double-blind, crossover trial.
Therapeutic response was assessed using the Conners’ Global Index for parents (CGI-Parents) and teachers (CGI-
Teachers), while side effects were assessed using the Barkley Side Effects Rating Scale (SERS).
Results: The side effect profile as assessed by the SERS was similar to that of previous studies with insomnia,
decreased appetite, and headaches showing significant treatment effects (p < 0.005). These “somatic/physical” side
effects did not correlate with CGI-Parents or CGI-Teachers. However, the side effects of “irritability”, “proneness to
crying”, and “anxiousness” showed significant relationships with CGI-Parents. These “mood/anxiety” side effects
showed no significant correlations with the CGI-Teachers.
Conclusion: The greater “mood/anxiety” side effects on methylphenidate and placebo, the less the parents
observe improvement of their children while treated with methylphenidate. This suggests that the correlations
between “mood/anxiety” side effects and poor response to treatment may be driven by observer effects rather
than biological commonalities between therapeutic and side effects of methylphenidate.
Background
Attention-deficit/hyperactivity disorder (ADHD) is a
common neurobehavioural disorder, characterized by
inattention, and/or impulsivity/hyperactivity, and emo-
tional instability. It is one of the most prevalent child-
hood psychiatric disorders, affecting 5-6% of school-
aged children worldwide [1].
The reported diagnosis of the disorder has increased
several-fold in the past 2 decades, and there has been
lingering public concern over the concurrent increase in
prescriptions for stimulant medication for children who
are afflicted by the disorder [2-4]. The most common
medication prescribed for children with ADHD is the
psychostimulant methylphenidate (MPH) [5-8]. MPH
has been shown to exhibit its therapeutic response in
approximately 70% of patients [9-11], though it also has
a number of known side effects [12,13]. Therapeutic
response to MPH includes a reduction of motor hyper-
activity, more focused task-oriented behavior, reduction
of impulsive behavior and emotional lability [14-16]. It
has also been reported that MPH may improve neurop-
sychological performance on measures of executive
function [17]. The extent of therapeutic response to
MPH may vary from one patient to the other.
Although therapeutic response to MPH has been
widely investigated, there have been only a few studies
examining the side effect profile for MPH. These studies
have noted a side effect profile characterized by a signif-
icant increase in frequency and severity of insomnia,
decreased appetite, headaches, and stomachaches, when
compared to placebo [12,18-20]. These effects are also
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any medium, provided the original work is properly cited.variable from one patient to the other, and the correla-
tions of these side effects with therapeutic effects were
not explored in previous studies.
MPH has been shown to block the dopamine (DA)
and norepinephrine (NE) transporters [21], resulting in
increased synaptic DA and NE concentration in different
brain regions including the prefrontal cortex [22]. This
increased neurotransmitter concentration likely results
in the modulation of various behaviors, both desired
(therapeutic) and undesired (side effects) and physical
manifestations. Thus, it may be hypothesized that thera-
peutic and undesirable effects of MPH may be corre-
lated through common biological mechanisms. In
addition, the evaluation of the therapeutic response and
side effects is often reported by the parents of the child
with ADHD. This may also lead to some correlation
between therapeutic and side effects.
The aim of this study was to explore the correlation
between the side effects observed while the child was
treated with MPH and the therapeutic response as
judged by parents. If such a correlation exists, it may
reflect both common biological mechanisms underlying
therapeutic and side effects as well as correlation in par-
ental assessment of therapeutic and side effects. We also
postulated that if the correlation between therapeutic
and side effects is at least partly due to observer (par-
ents) effects, it will be stronger for the correlation
between parent’s evaluation of therapeutic and side
effects, compared to the correlation between therapeutic
effects as assessed by teachers and side effects as
assessed by parents.
Methods
Subjects
Children between the ages of 6 and 12 years of age were
recruited from the child psychiatry outpatient clinic and
the Disruptive Behavior Disorders Program at the Dou-
glas University Institute of Mental Health, an affiliate
psychiatric teaching Institute of McGill University in
Montreal. The children were referred from schools, spe-
cialized care facilities, general practitioners or pediatri-
cians. These children and their parents were interviewed
by an experienced child psychiatrist. Approximately 95%
of all eligible patients who met the study criteria agreed
to participate with relevant data obtained from 157
patients. A wide spectrum of severity was observed from
mild to the severely ill.
Screening
All children were diagnosed with ADHD, in concor-
dance with DSM-IV criteria [23]. The diagnosis was
based on the Diagnostic Interview Schedule for Children
Version 4 (DISC-IV) [24] (parent report), and a clinical
interview by a child psychiatrist. Exclusion criteria for
the study included an IQ less than 70 on the WISC-III
[25], Tourette’s syndrome (TS), pervasive developmental
disorder, and psychosis. Children were also excluded
from the study if they were concurrently prescribed any
medication other than MPH or had a previous history
of intolerance or allergic reactions to psychostimulants.
None of the children had to be excluded from the study
due to severity of side effects experienced from any pre-
vious treatment. Written informed consent was provided
by the parents, and all children verbally agreed to parti-
cipate in the trial with MPH. Approval for the study
was granted by the Research Ethics Board of Douglas
Hospital.
Assessments
Parents completed a Child Behavioral Checklist [26],
which assesses several behavioral domains, and the Con-
ners’ Global Index for parents (CGI-Parents) [27]. The
CGI-Parents is a widely used rating scale to assess
symptoms of ADHD and other psychopathology in chil-
dren between 3 and 17 years of age. The CGI scale is
comprised of 10 items representing the Hyperactivity
Index of the original Conners’ scale. Each of the items
describes a behavior that is rated on a 4-point Likert
scale from 0 (not at all true) to 3 (very much true). The
CGI-Parents is comprised of 2 factors: ‘Emotional labi-
lity’ and ‘Restless-impulsive behavior’. Raw total and fac-
tor scores are transformed into normalized T-scores. A
score of 65 or higher is considered to be clinically sig-
nificant. The teachers also completed the CGI-teacher
[28], which is equivalent to CGI-parents and has the
same metric characteristics.
Parents also completed the Side Effects Rating Scale
[12], which is composed of 17 side effects commonly
associated with MPH treatment. Side effects were ranked
on a 9-point scale from mild (score = 1) to most severe
(score = 9). Scores above 7 were considered to be severe.
Design
The study was a double-blind, placebo-controlled, cross-
over, randomized trial. Baseline assessments were made
following a two-week washout period and 1 week before
the trial began, while the child was not on any medica-
tion. Children then received, by random assignment,
either placebo or 0.5 mg/kg/day MPH in a divided b.i.d.
dose over a 1-week period, after which they were
crossed over for the second week treatment. All treat-
ments were prepared in identical gelatin capsules by a
pharmacist who was not otherwise involved in the
research project. Treatments (MPH and placebo) were
packaged in individual blisters, which were clearly
labeled and given to parents on the first day of the
study. Blister packs were collected at the end of the
two-week study to verify the compliance to treatment.
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Chi Squared analyses were conducted to contrast fre-
quencies of the 17 side effects, as well as the frequencies
of severe side effects, between the placebo and active
conditions. Repeated measures analysis of variance
(ANOVA) was used to detect the effects of treatment,
order of treatment, and the interaction between these
two variables on the mean severity ratings for each of
the 17 side effects. Effect size (Cohen’s d) was also
determined from the mean severity ratings and standard
deviation of the side effects observed in the placebo and
active conditions. Pearson correlations were conducted
to investigate correlations between the side effect scores
and the response to the treatment, as reported by par-
ents and teachers, for each of the different side effects.
For each statistical analyses, significance was judged at
a = 0.005, to account for multiple testing (0.05/17 com-
parisons ~ 0.005).
Results
Demographic and clinical characteristics of sample
As expected, children treated with MPH as compared to
placebo had significant improvement in ADHD symp-
toms as assessed by parents and teachers (p < 0.005).
Among the 157 parent evaluations, the majority of the
evaluations were done by mothers (n = 137). Only a
minority of children were evaluated by fathers alone (n
= 8) or both parents (n = 12). Table 1 shows the demo-
graphic and clinical characteristics of the patients.
46.7%, 42.4%, 10.9% of children were diagnosed with the
combined, inattentive and hyperactive types of ADHD
respectively. The frequency of oppositional defiant
disorder and conduct disorder were 41.8% and 24.2%,
respectively.
The percent occurrence for all 17 side effects listed in
the Side Effect Rating Scale (SERS) was calculated for
those who had parent ratings of 1 or higher. The per-
cent occurrence was also calculated for parent ratings of
7 or higher to establish the frequency of severe side
effects to the treatments. The results are shown in
Table 2. Of the 17 side effects, only insomnia and
decreased appetite were significantly more frequent (p <
0.005), in the week of treatment with MPH compared to
placebo. However, the percentage of children experien-
cing headaches and the talks less side effects increased
by 11% and 10%, respectively (p < 0.05). Interestingly,
the side effect of euphoria decreased in incidence from
31% to 20% (p < 0.05). The remaining 12 side effects
did not show a significant change in frequency over the
placebo and medication conditions. Among the severe
side effects, significant difference between placebo and
MPH weeks were observed for decreased appetite (4%
versus 17%, p < 0.005) and severe headaches (2% versus
8%, p < 0.05).
Table 1 Clinical and demographic characteristics of
children with attention deficit hyperactivity disorder
Clinical characterisitics Mean (SD)
Age, y 8.97 (1.82)
IQ (WISC-III Full Scale) 99.88 (14.94)
Mother’s age, y 36.36 (6.18)
Mother’s education, y 12.57 (3.16)
CBCL scales
Aggression 72.76 (11.94)
Attention Problems 71.70 (9.62)
CPRS scales
Restless-Impulsive 75.35 (9.62)
Emotional Lability 68.03 (12.83)
CTRS scales
Restless-Impulsive 68.45 (10.91)
Emotional Lability 67.55 (16.13)
*WISC-III, Wechsler Intelligence Scale for Children; CBCL, Child Behavior
Checklist; CPRS, Conners Parent Rating Scale; CTRS, Conners Teacher Ratings
Scale.
Table 2 Percentage of subjects displaying each of the 17
side effects of methylphenidate during each treatment
condition (Parent Ratings)*
Side Effect Total Side Effects Severe Side Effects
Placebo Active P-
value
Placebo Active P-
value
Insomnia (%) 25 47 0,00 7 13 0,08
Nightmares (%) 15 12 0,39 2 1 0,68
Stares a lot (%) 26 31 0,30 4 4 0,96
Talks less (%) 13 23 0,01 2 4 0,49
Uninterested (%) 15 14 0,69 2 3 0,46
Decreased
Appetite (%)
20 49 0,00 4 17 0,00
Irritable (%) 52 54 0,68 12 10 0,57
Stomachaches (%) 17 25 0,10 4 4 0,92
Headaches (%) 19 31 0,01 2 8 0,02
Drowsiness (%) 8 14 0,09 0 2 0,08
Sadness (%) 27 30 0,57 4 8 0,09
Prone to crying
(%)
32 43 0,05 7 6 0,88
Anxious (%) 37 34 0,54 7 4 0,25
Bites fingernails
(%)
21 22 0,86 8 8 0,76
Euphoria (%) 31 20 0,03 8 5 0,21
Dizziness (%) 7 5 0,39 0 1 0,15
Tics/Nervous
movements (%)
14 15 0,93 4 2 0,33
* % refers to the percentage of subjects in whom the side effect was rated 1
or higher on the scale of severity (1 to 9); % severe refers to the percentage
of subjects in whom the side effect was rated 7 or higher.
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17 side effects were subjected to 2-way repeated mea-
sures ANOVA to analyze the effect of treatment and to
test for any effect of order of treatment. The results are
shown in Table 3. It was observed that the side effects
that significantly increased in severity with MPH treat-
ment were decreased appetite, insomnia,a n dheadaches
(in decreasing order of effect size), at p < 0.005. The
side effects of talks less and euphoria also had significant
changes, at p < 0.05, with the former increasing nearly
two-fold from 0.50 to 0.98, and the latter decreasing
from 1.49 to 0.98. The effect of the order of treatment,
and its the interaction with the treatment effect were
not statistically significant.
Pearson correlations were conducted between side
effects assessed by parents and the CGI-P ratings (as
well as the factors scores for Restless-Impulsive and
Emotional Lability), for each of the placebo and MPH
weeks (Table 4). The CGI-P response to MPH was cal-
culated as the difference between CGI-P during the pla-
cebo week and during the MPH week. Significant
negative correlations were observed between the CGI-P
response to MPH and the SERS parent ratings (placebo
-M P H )f o rirritability, prone to crying,a n danxiousness
(p < 0.005). The poorer the therapeutic response, the
higher these side effects were. Interestingly, side effects
that revealed significant results for frequency and mean
severity ratings over placebo (insomnia, decreased appe-
tite, headaches) did not show any significant correlations
with the parent ratings for the response to treatment.
Table 5 shows Pearson correlations between side
effects assessed by parents during the placebo week and
the MPH week and CGI-T ratings during the placebo
week and the MPH week. Only one significant negative
correlation was found between the CGI-T (restless-
impulsive factor) to MPH and the SERS parent ratings
(placebo) for tics/nervous movements (p < 0.005).
Discussion
The results of the present study confirmed a similar side
effect profile to those of previous studies [12,13,29], with
the side effects of insomnia and decreased appetite hav-
ing significantly greater prevalence in the MPH condi-
tion than the placebo condition.
The purpose of the correlation analyses was to investi-
gate any relationships between the side effects observed
while on MPH and the therapeutic response, as judged
by parents through the SERS and CGI-P, respectively.
The analysis yielded significant negative correlations
between the response to MPH (CGI-P, emotional liabi-
lity) and the side effects of irritability (also significant
correlation with CGI-P, restless-impulsive), proneness to
crying,a n danxiousness. However, what is striking is
that the most frequently reported side effects of
Table 3 Mean Severity Ratings by Parents for Each of 17 Side Effects for Each Drug Condition
Side Effect Placebo
mean ±
(SD)
MPH
mean ±
(SD)
Treatment
Effect
P-
value
Order
Effect
P-
value
Treatment and Order
Interaction
P-
value
Effect
Size
Decreased appetite 0,84 ± 1,95 2,55 ± 3,06 F = 59,9 0,00 F = 0,1 0,71 F = 2,3 0,13 0,67
Insomnia 1,18 ± 2,35 2,25 ± 2,94 F = 19,7 0,00 F = 1,3 0,25 F = 0,1 0,73 0,40
Headaches 0,60 ± 1,59 1,28 ± 2,45 F = 9,6 0,002 F = 0,8 0,38 F = 0,4 0,51 0,33
Talks less 0,50 ± 1,61 0,98 ± 2,04 F = 5,2 0,02 F = 3,5 0,06 F = 0,4 0,53 0,26
Drowsiness 0,33 ± 1,21 0,52 ± 1,47 F = 2,5 0,11 F = 0,7 0,41 F = 0,2 0,67 0,14
Sadness 1,03 ± 2,00 1,27 ± 2,40 F = 1,1 0,30 F = 0,6 0,43 F = 2,6 0,11 0,11
Anxious 1,55 ± 2,50 1,31 ± 2,19 F = 1,3 0,26 F = 0,3 0,59 F = 5,0 0,03 0,10
Prone to crying 1,36 ± 2,41 1,61 ± 2,40 F = 0,9 0,35 F = 0,5 0,48 F = 4,6 0,03 0,10
Nightmares 0,43 ± 1,38 0,31 ± 1,19 F = 0,6 0,46 F = 2,0 0,16 F = 1,2 0,27 0,09
Stomachaches 0,67 ± 1,86 0,83 ± 1,90 F = 0,5 0,48 F = 6,7 0,01 F = 1,1 0,30 0,09
Stares a lot 1,05 ± 2,04 1,17 ± 2,09 F = 0,4 0,54 F = 0,3 0,61 F = 0,01 0,91 0,06
Uninterested 0,55 ± 1,50 0,65 ± 1,86 F = 1,0 0,33 F = 0,2 0,62 F = 0,8 0,37 0,06
Bites fingernails 1,15 ± 2,50 1,11 ± 2,40 F = 0,03 0,85 F = 0,6 0,45 F = 1,1 0,29 0,02
Dizziness 0,19 ± 0,82 0,20 ± 1,00 F = 0,0 0,98 F = 1,0 0,32 F = 0,8 0,36 0,01
Irritable 2,42 ± 2,85 2,41 ± 2,77 F = 0,2 0,64 F = 0,2 0,69 F = 2,1 0,15 0,00
Tics/nervous
Movements
0,64 ± 1,77 0,60 ± 1,63 F = 0,1 0,75 F = 1,3 0,26 F = 0,03 0,85 0,02
Euphoria 1,49 ± 2,55 0,98 ± 2,17 F = 5,6 0,02 F = 0,01 0,92 F = 0,1 0,71 0,21
Side Effects are Ordered by Effect Size.
Effect Size (Cohen’s d) value from the means and standard deviations of Placebo and MPH.
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Placebo Active Placebo-Active
Side Effect CGI-P
(RI)
P-
value
CGI-P
(EL)
P-
value
CGI-P
(RI)
P-
value
CGI-P
(EL)
P-
value
CGI-P
(RI)
P-
value
CGI-P
(EL)
P-
value
Insomnia -0,13 0,10 -0,13 0,11 0,03 0,75 0,06 0,43 0,04 0,67 0,16 0,06
Nightmares -0,14 0,08 -0,13 0,12 -0,02 0,78 -0,15 0,07 0,03 0,75 -0,10 0,25
Stares a lot -0,07 0,37 0,06 0,44 -0,05 0,53 -0,03 0,74 -0,09 0,30 0,00 0,99
Talks less 0,01 0,88 0,06 0,47 0,07 0,41 0,10 0,20 0,12 0,15 0,10 0,23
Uninterested -0,11 0,17 -0,09 0,27 -0,02 0,84 -0,01 0,94 -0,08 0,34 -0,03 0,74
Decreased Appetite 0,07 0,41 -0,10 0,21 0,14 0,10 -0,01 0,87 0,17 0,04 0,02 0,83
Irritable -0,18 0,03 -0,19 0,02 -0,19 0,02 -0,15 0,08 -0,24 0,00 -0,26 0,00**
Stomachaches 0,02 0,79 -0,05 0,58 0,13 0,12 0,02 0,77 0,19 0,03 0,06 0,47
Headaches -0,03 0,71 0,00 0,96 -0,16 0,05 -0,14 0,10 -0,13 0,11 -0,17 0,05
Drowsiness -0,17 0,04 -0,08 0,31 0,14 0,10 0,00 0,97 0,07 0,43 -0,09 0,28
Sadness -0,15 0,07 -0,20 0,01 0,03 0,68 -0,13 0,11 -0,04 0,65 -0,21 0,01
Prone to crying -0,09 0,28 -0,18 0,03 -0,03 0,70 -0,16 0,04 -0,07 0,42 -0,39 0,00**
Anxious -0,20 0,02 -0,08 0,35 -0,01 0,90 -0,12 0,16 -0,20 0,02 -0,30 0,00**
Bites fingernails -0,08 0,31 0,00 0,96 -0,02 0,82 0,09 0,27 -0,01 0,93 0,08 0,37
Euphoria -0,07 0,37 -0,06 0,43 0,00 1,00 0,12 0,14 -0,11 0,22 0,00 0,99
Dizziness -0,01 0,89 0,03 0,72 0,00 0,97 0,02 0,78 0,01 0,95 0,03 0,76
Tics/Nervous
movements
-0,02 0,84 -0,02 0,78 -0,04 0,59 -0,21 0,01 -0,10 0,25 -0,18 0,04
* CGI-P, Conners Global Index-Parents; RI, Restless-Impulsive; EL, Emotional Lability, ** p < 0,005.
Table 5 Correlation Between Therapeutic Response (CGI-T*) and Side Effects as Rated by Parents
Placebo Active Placebo-Active
Side Effect CGI-P
(RI)
P-
value
CGI-P
(EL)
P-
value
CGI-P
(RI)
P-
value
CGI-P
(EL)
P-
value
CGI-P
(RI)
P-
value
CGI-P
(EL)
P-
value
Insomnia 0,19 0,03 0,08 0,39 -0,14 0,10 -0,22 0,01 0,02 0,84 -0,10 0,25
Nightmares -0,02 0,79 0,04 0,66 0,01 0,91 0,06 0,53 -0,10 0,27 0,04 0,69
Stares a lot -0,05 0,60 0,12 0,18 0,05 0,60 -0,09 0,32 0,02 0,85 -0,06 0,52
Talks less -0,08 0,37 0,00 0,98 -0,07 0,44 -0,22 0,01 -0,05 0,61 -0,12 0,20
Uninterested -0,08 0,36 -0,05 0,59 -0,03 0,74 0,00 1,00 -0,11 0,24 -0,24 0,01
Decreased Appetite 0,12 0,18 0,06 0,50 0,03 0,78 -0,05 0,61 0,12 0,18 0,03 0,74
Irritable 0,05 0,53 0,15 0,09 -0,02 0,85 0,00 0,97 -0,03 0,71 -0,14 0,11
Stomachaches -0,02 0,84 -0,09 0,28 0,02 0,80 -0,09 0,31 -0,07 0,48 -0,13 0,14
Headaches 0,09 0,28 0,03 0,75 -0,02 0,81 -0,10 0,23 -0,01 0,93 -0,08 0,39
Drowsiness 0,08 0,36 0,04 0,62 0,05 0,58 -0,05 0,61 0,11 0,24 0,01 0,95
Sadness 0,13 0,12 0,12 0,15 0,06 0,50 0,03 0,71 0,03 0,74 -0,11 0,21
Prone to crying -0,14 0,10 -0,02 0,82 0,01 0,92 -0,07 0,43 -0,05 0,62 -0,13 0,16
Anxious -0,02 0,80 0,18 0,03 0,11 0,19 0,00 1,00 0,01 0,94 -0,09 0,32
Bites fingernails -0,11 0,19 -0,04 0,69 0,12 0,16 0,01 0,91 -0,12 0,20 -0,14 0,12
Euphoria -0,13 0,13 -0,08 0,33 0,06 0,49 0,06 0,48 -0,21 0,02 -0,15 0,09
Dizziness 0,19 0,03 0,07 0,42 -0,04 0,62 -0,09 0,29 0,06 0,48 0,05 0,62
Tics/Nervous
movements
-0,30 0,00** -0,07 0,39 0,03 0,73 0,01 0,89 -0,03 0,73 0,04 0,68
* CGI-T, Conners Global Index-Teachers; RI, Restless-Impulsive; EL, Emotional Lability, ** p < 0,005.
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show a significant correlation. Thus, it appears that the
more “mood/anxiety” side effects, such as irritability,
proneness to crying, and anxiousness, do affect how par-
ents judge the behavioral improvement. This interpreta-
tion of the results is further supported by the fact that
side effects such as irritability, proneness to crying, and
anxiousness are far more non-specific. Furthermore,
these side effects did not show a significant change in
frequency or severity while on MPH, when compared to
placebo, despite being the most frequently reported side
effects (with the exception of decreased appetite and
insomnia). This could mean that it is not MPH that is
causing an increase in parent-reported irritability,
anxiousness, or proneness to crying, but the fact that
they were given any treatment at all, whether it is in the
form of MPH or placebo.
We postulated initially that the relationships found
between side effects and the parent-rated therapeutic
response could be due to a shared biological mechan-
ism, meaning that with increased therapeutic effects
there will be also increased side effects. However, if this
w e r et r u e ,w ew i l le x p e c tt h a tt h es a m ec o r r e l a t i o n s
found between side effects and the parent-rated thera-
peutic response should have been found with the tea-
cher-rated therapeutic response. This correspondence
was not observed in the correlational analysis. Thus, the
relationships between side effects and the parent-rated
therapeutic response are not likely due to common bio-
logical mechanisms, but are more an effect of the paren-
tal evaluation itself. The greater “mood/anxiety” sides
effects on methylphenidate and placebo, the less the
parents observe improvement of their children while
treated with methylphenidate.
There are several limitations to our study that should
be mentioned. The first is that while the method is
experimentally appropriate, giving children 0.5 mg/kg
for a 1- week period deviates from common clinical
practice. Studies investigating a wider dosage range and
longer period of treatment would be required to deter-
mine whether stronger significant correlations between
side effects induced by and therapeutic effects of
methylphenidate exist.
Another limitation is the use of only the parent report
for the side effects data. The American Academy of
Pediatrics practice guidelines call for a multimodal
assessment battery to monitor treatment effects, such as
teachers, and other caretakers in the child’s environment
[30]. Although teachers are better informants regarding
treatment response, parents are better informants
regarding the adverse effects of medication [31]. This
could be due to children being more comfortable com-
plaining about adverse effects to their parents than to
their teachers.
There are a few other limitations which could modify
or even mediate some of the correlations observed in
this study. The study design does not include a measure
of parents’ treatment expectations and the presence of
ADHD among parents. Finally, the majority of parental
evaluations were done by mothers or both parents
together, and we did not have data on the teachers’ gen-
der. This precluded us from using gender (parents and
teachers) as a covariate in the analyses.
Conclusion
The conclusion of our study is of relevance to the relia-
bility of parent reports, in that they appear to be influ-
enced not by the more physical side effects to the MPH,
but by the more non-specific behavioural side effects.
These mood/anxiety side effects were just as prevalent in
the placebo condition, further emphasizing the influence
of the placebo effect on any medication therapy. Further-
more, the results suggested that it is not likely that there
is a common biological mechanism between the thera-
peutic response and side effects, particularly objective/
physical side effects. One possible mechanism linking
mood/anxiety side effects to poor therapeutic response as
judged by parents is that anxiety might be a shared trait
between the child and his parents. If so, anxious parents
may become more anxious when faced with giving treat-
ment to their children, which may exacerbate the anxiety
of the child during both weeks of treatment. Anxious
p a r e n t st e n dt ob eh y p e r - v i g i l a n ta b o u ts i d ee f f e c t si n
their children. If they detect that their child is more irri-
table, anxious or teary, they may tend to judge negatively
the effect of the treatment. The results from this study
emphasize the need for further examination of the many
factors that may influence the evaluation of the therapeu-
tic response to MPH and similar drugs.
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